Non-Achievement of Low-Density Lipoprotein Cholesterol Management Goals Authors: Kazuhisa Tsukamoto, Takuya Maekawa, Miyuki Matsukawa, Yumiko Nakamura, Yoshikazu Nishimura, Shun Kohsaka Published: 2026 ABSTRACT BackgroundLow-density lipoprotein cholesterol (LDL-C) is an established therapeutic target for atherosclerotic cardiovascular diseases (ASCVD), particularly in high-risk individuals. In 2022, the Japan Atherosclerosis Society Guidelines (JAS-GL) for Prevention of Atherosclerotic Cardiovascular Diseases introduced more stringent LDL-C targets to reduce ASCVD. We evaluated the non-achievement rates of the LDL-C goals across risk groups using a nationwide real-world dataset, which included a broad range of ASCVD patients.Methods and ResultsThis retrospective, cross-sectional study included 200,607 adults (aged ≥18 years) with dyslipidemia. Patients were stratified according to the JAS-GL 2022 into a high-risk primary prevention population (Groups I, II, and familial hypercholesterolemia [FH]: no history of coronary artery disease [CAD] or stroke, classified by comorbidities such as diabetes), and a secondary prevention population (Groups III and IV: history of CAD or stroke, with Group IV having additional conditions such as diabetes). The primary endpoint was the proportion of patients who did not achieve their target LDL-C goals. Non-achievement rates were 28.2% (Group I), 46.7% (Group II), 64.3% (Group FH), 30.0% (Group III), and 65.6% (Group IV). Importantly, these rates remained high and showed little change before and after the revision of the guidelines across all studied risk groups.ConclusionsNon-achievement of LDL-C targets remained high despite updated recommendations. These findings highlight a need for more effective implementation strategies and sustained efforts to improve lipid management. Central Figure According to the 2023 vital statistics, cardiovascular disease (CVD) is the second leading cause of death in Japan,1 and the long-term care costs associated with CVD account for a larger proportion of the total burden than those for cancer, which is the leading cause of death.2 CVD includes conditions such as coronary artery disease (CAD), stroke, heart failure, arrhythmia, and peripheral artery disease (PAD). Among these, atherosclerotic cardiovascular diseases (ASCVD) constitute a major subset and are specific types of CVD caused by atherosclerosis – a process in which plaque (composed of fat, cholesterol, and other substances) accumulates within the arterial walls, leading to narrowing and reduced blood flow.3 Elevated levels of low-density lipoprotein cholesterol (LDL-C) play a critical role in the development of atherosclerotic plaques, promoting the narrowing and hardening of arteries. This process significantly increases the risk of ASCVD events. Accordingly, LDL-C is recognized as a key therapeutic target for the prevention and management of ASCVD, particularly in individuals at high risk.3 Elevated LDL-C levels have been reported to increase the risk of CAD,4 and lowering LDL-C by 1.0 mmol/L with treatment is associated with approximately 20% reduction in yearly cardiovascular event rates.5 Accordingly, the 2022 Japan Atherosclerosis Society Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases (JAS-GL 2022) established detailed treatment targets, and introduced a subcategory within the high-risk category of the primary prevention population, for which LDL-C should be more strictly controlled.6 This subcategory includes patients with diabetes complicated by PAD or microangiopathy, as well as current smokers. In addition, the scope of the secondary prevention population has been broadened beyond patients with CAD to include those with a history of atherothrombotic stroke. Furthermore, the JAS-GL 2022 set lower LDL-C targets for patients with high-risk conditions among the secondary prevention population, such as acute coronary syndrome (ACS), familial hypercholesterolemia (FH), diabetes, or the coexistence of CAD and atherothrombotic stroke.6 However, there have been no reports on the achievement of the newly defined LDL-C management goals in the JAS-GL 2022. In this study, using a real-world medical database, we aimed to clarify the actual state of LDL-C management in patients with dyslipidemia by calculating the non-achievement rates of the LDL-C goals for high-risk conditions in patients with dyslipidemia, as defined by the JAS-GL 2022. Methods Data Source The data source for this study was an anonymized large-scale diagnosis procedure combination (DPC) database provided by Medical Data Vision Co., Ltd (MDV; Tokyo, Japan). Among large-scale DPC databases, the MDV database is the largest in Japan, and contains information on 47.79 million people from 512 acute care hospitals. This represents approximately 29% of Japanese acute care hospitals that have adopted the DPC as of March 31, 2024. The period of data for this study was from March 1, 2022 to March 31, 2024. Ethics This study was approved by the ethical review committee of Kitamachi Clinic, Fujikei Medical Corporation (approval no. OTH10810) and was conducted in accordance with the Declaration of Helsinki and the ethical guidelines for life science and medical research involving human subjects. The study was registered at the University Hospital Medical Information Network (https://www.umin.ac.jp/) under the identifier number UMIN000058425. Study Design and Study Population This retrospective, cross-sectional study included patients who underwent LDL-C tests between August 1, 2022, and March 31, 2024 (Figure 1). If patients underwent multiple tests, the most recent test date was defined as the index date. Patients were included if they were aged ≥18 years as of the index date, with a diagnosis of dyslipidemia (International Classification of Diseases, 10th edition [ICD-10]; ICD-10 code E78), and met any of the following criteria: patients with a history of CAD or atherothrombotic brain infarctions (ATBIs; including other brain infarctions with evident atheroma) before the index date, or patients without a history of these diseases but with comorbidities of diabetes (excluding glucose intolerance), chronic kidney disease (CKD), PAD, or FH. The definitions of CAD, CKD, PAD, FH, and other comorbidities used in this study are provided in Supplementary Table 1. Figure 1.Study design. The index date (Day 0) was defined as the date of the most recent measurement of low-density lipoprotein cholesterol (LDL-C). For the analysis of non-achievement rates by period, the index date was identified within the timeframe of March 1, 2022 to March 31, 2024 (Figure 5). ICD-10, International Classification of Diseases, 10th Revision; LLT, lipid-lowering therapy (refer to Supplementary Table 2). Study design. The index date (Day 0) was defined as the date of the most recent measurement of low-density lipoprotein cholesterol (LDL-C). For the analysis of non-achievement rates by period, the index date was identified within the timeframe of March 1, 2022 to March 31, 2024 (Figure 5). ICD-10, International Classification of Diseases, 10th Revision; LLT, lipid-lowering therapy (refer to Supplementary Table 2). Based on the JAS-GL 2022, patients were stratified into the following risk groups: I; II; FH; III; and IV (Table 1). Groups I, II and FH were classified under the high-risk category within the primary prevention population, whereas Groups III and IV were classified under the secondary prevention population. Table 1.Definitions of Each Analysis PopulationGroupDefinitionTarget LDL-C goal (mg/dL)IPatients with no history of CAD or atherothrombotic brain infarction before the index date, who had comorbid diabetes, CKD, or PAD and were confirmed to not have FH<120IIPatients in Group I who had comorbid diabetes before the index date and who also had PAD or microangiopathy (retinopathy, nephropathy, or neuropathy)<100FHPatients with no history of CAD or atherothrombotic brain infarction before the index date but with FH<100IIIPatients with a confirmed diagnosis of CAD or atherothrombotic brain infarction (including other brain infarction with evident atheroma) before the index date<100IVAmong Group III patients, those who had a recorded diagnosis of ACS, FH, or diabetes prior to the index date, or who were confirmed to have both CAD and atherothrombotic brain infarction (including other brain infarction with evident atheroma) before the index date<70ACS, acute coronary syndrome; CAD, coronary artery disease; CKD, chronic kidney disease; FH, familial hypercholesterolemia; LDL-C, low-density lipoprotein cholesterol; PAD, peripheral artery disease. Table 1.Definitions of Each Analysis PopulationGroupDefinitionTarget LDL-C goal (mg/dL)IPatients with no history of CAD or atherothrombotic brain infarction before the index date, who had comorbid diabetes, CKD, or PAD and were confirmed to not have FH<120IIPatients in Group I who had comorbid diabetes before the index date and who also had PAD or microangiopathy (retinopathy, nephropathy, or neuropathy)<100FHPatients with no history of CAD or atherothrombotic brain infarction before the index date but with FH<100IIIPatients with a confirmed diagnosis of CAD or atherothrombotic brain infarction (including other brain infarction with evident atheroma) before the index date<100IVAmong Group III patients, those who had a recorded diagnosis of ACS, FH, or diabetes prior to the index date, or who were confirmed to have both CAD and atherothrombotic brain infarction (including other brain infarction with evident atheroma) before the index date<70ACS, acute coronary syndrome; CAD, coronary artery disease; CKD, chronic kidney disease; FH, familial hypercholesterolemia; LDL-C, low-density lipoprotein cholesterol; PAD, peripheral artery disease. Definitions of Each Analysis Population ACS, acute coronary syndrome; CAD, coronary artery disease; CKD, chronic kidney disease; FH, familial hypercholesterolemia; LDL-C, low-density lipoprotein cholesterol; PAD, peripheral artery disease. Lipid-Lowering Therapy (LLT) Medications for LLT are defined in Supplementary Table 2. These medications were selected from those listed as treatments for dyslipidemia in the JAS-GL 2022.6 Outcomes The primary endpoint was the proportion of patients in each group who did not meet their target LDL-C goals at the index date. The target LDL-C goals were set at <120, <100, <100, <100, and <70 mg/dL for Groups I, II, FH, III, and IV, respectively (Table 1). For each group and for each subgroup further defined by prior history or comorbidities, we calculated the proportion of patients who did not achieve their target LDL-C goals. It should be noted that in the subgroup analyses, patients were represented in multiple subgroups due to overlapping characteristics. Accordingly, the calculation of the proportion of patients not achieving target LDL-C in each subgroup reflects this overlap. The exploratory outcome was the proportion of patients who did not achieve LDL-C targets in each group during the 5 consecutive study periods: Period 1 – March 1, 2022 to July 31, 2022; Period 2 – August 1, 2022 to December 31, 2022; Period 3 – January 1, 2023 to May 31, 2023; Period 4 – June 1, 2023 to October 31, 2023; and Period 5 – November 1, 2023 to March 31, 2024. Patient management was conducted in accordance with the 2017 guidelines prior to their revision on July 4, 2022. The revised JAS-GL 2022 guidelines were implemented on July 4, 2022. Thus, Period 1 reflects management under the previous 2017 guidelines, while Periods 2–5 correspond to the post-revision era under the updated guidelines. Statistical Analysis The study was principally descriptive, and no statistical hypotheses were tested. Patient baseline characteristics were summarized as counts and percentages for categorical variables, and mean±standard deviation (SD) for continuous variables. Comorbidity was assessed with the Charlson Comorbidity Index (CCI), the most widely accepted tool used to assess comorbidities and predict mortality risk in clinical research (Supplementary Table 3). In the primary analysis, the proportion of patients who did not achieve target LDL-C goals was calculated for each risk group as the percentage of patients in that group, and the corresponding 95% confidence interval (CI) was estimated. For sensitivity analyses, and in accordance with the STROBE statement’s recommendations,7 2 alternative datasets were constructed to evaluate potential misclassification bias in disease identification: (1) a ‘dyslipidemia’ dataset in which patients were required to have an ICD-10 code for dyslipidemia (E78) before the index date and at least 1 prescription for LLT before that date; and (2) a ‘CAD’ dataset in which CAD was defined by the presence of both an ICD-10 diagnosis code and a relevant procedural code. Subgroup analyses were then performed within each risk group to assess the consistency of LDL-C non-achievement trends across different clinical backgrounds. Subgroups were defined as follows: Group I – patients with diabetes, CKD, and PAD; Group II – patients with diabetes and PAD, and diabetes and microangiopathy; Group III – patients with prior CAD, and prior ATBI; and Group IV – patients with a history of ACS, FH, a history of diabetes, and a history of both CAD and ATBI. Each subgroup’s LDL-C goal was set to the same value as that of its parent risk group. As an additional exploratory analysis – based on the hypothesis that guideline recommendations would be progressively adopted in practice after the publication of the JAS-GL 2022 – the overall study period was divided into 4 equal 5-month intervals. Within each interval, we descriptively assessed the LDL-C non-achievement rates among patients meeting the inclusion criteria. To characterize baseline practice prior to the guideline revision, we also defined a pre-publication interval and calculated the non-achievement rates for that period, thereby enabling a descriptive comparison of lipid management before and after guideline release. No imputation was performed for missing data. All analyses were conducted using SAS version 9.4 (SAS Institute Japan). Results Patient Population During the study period, there were 2,476,817 patients with dyslipidemia, of whom 277,814 had LDL-C test results. Of these, 200,607 patients met the inclusion criteria (Figure 2). Based on the JAS-GL 2022, patients in the primary prevention population were divided into 3 groups: Group I (n=101,001); Group II (n=21,907); and Group FH (n=745), all of which belonged to the high-risk category. Patients in the secondary prevention population were classified into 2 groups: Group III (n=98,861); and Group IV (n=63,273; Figure 2). The definitions and the target LDL-C goals for each analysis group are shown in Table 1. Figure 2.Patient flowchart. CKD, chronic kidney disease; FH, familial hypercholesterolemia; LDL-C, low-density lipoprotein cholesterol; MCP, microangiopathy; PAD, peripheral artery disease. Patient flowchart. CKD, chronic kidney disease; FH, familial hypercholesterolemia; LDL-C, low-density lipoprotein cholesterol; MCP, microangiopathy; PAD, peripheral artery disease. Patient Characteristics Patient characteristics are shown in Table 2. Compared with Groups I and II, which belong to the high-risk category of the primary prevention population, the secondary prevention population (Groups III and IV) was predominantly male (66.4% and 69.6%, respectively) and comprised older patients (mean age 74.5 and 74.0 years, respectively). In contrast, patients in Group FH were more often female (63.4%) and substantially younger (mean age 59.5 years). The mean CCI was highest in Group IV (3.4) and lowest in Group FH (1.8), with all other groups exhibiting intermediate comorbidity burdens. Table 2.Clinical Characteristics of Patients Group I (n=101,001)Group II (n=21,907)Group FH (n=745)Group III (n=98,861)Group IV (n=63,273)Sex, male50,327 (49.8)12,276 (56.0)273 (36.6)65,624 (66.4)44,010 (69.6)Age (years)71.3±13.168.2±12.959.5±8.574.5±11.274.0±11.1CCI (before the index date)2.6±2.23.2±2.21.8±1.93.1±2.33.4±2.3eGFR (mL/min/1.73 m2) n90,37621,41965290,54459,672 Mean±SD56.6±23.461.4±27.170.4±23.856.0±22.655.1±23.4CKD stage G16,101 (6.0)2,376 (10.8)106 (14.2)4,614 (4.7)3,211 (5.1) G228,991 (28.7)9,394 (42.9)353 (47.4)34,773 (35.2)21,838 (34.5) G3a31,225 (30.9)4,591 (21.0)119 (16.0)26,011 (26.3)16,517 (26.1) G3b14,840 (14.7)2,526 (11.5)52 (7.0)14,514 (14.7)10,112 (16.0) G45,424 (5.4)1,259 (5.7)12 (1.6)6,029 (6.1)4,495 (7.1) G53,795 (3.8)1,273 (5.8)10 (1.3)4,603 (4.7)3,499 (5.5)Type of lipid-lowering therapy used within the 4 weeks before the index date None49,870 (49.4)8,145 (37.2)259 (34.8)42,241 (42.7)25,362 (40.1) Statin39,695 (39.3)10,769 (49.2)278 (37.3)41,021 (41.5)26,847 (42.4) Ezetimibe2,845 (2.8)719 (3.3)27 (3.6)1,729 (1.7)1,118 (1.8) PCSK9i or inclisiran2 (<0.1)0 (0.0)3 (0.4)21 (<0.1)16 (<0.1) Statin + ezetimibe2,287 (2.3)667 (3.0)149 (20.0)10,539 (10.7)8,031 (12.7) Statin + PCSK9i1 (<0.1)0 (0.0)0 (0.0)31 (<0.1)22 (<0.1) Ezetimibe + PCSK9i2 (<0.1)1 (<0.1)1 (0.1)11 (<0.1)5 (<0.1) Statin + ezetimibe + PCSK9i1 (<0.1)0 (0.0)2 (0.3)45 (<0.1)38 (<0.1) Other6,298 (6.2)1,606 (7.3)26 (3.5)3,223 (3.3)1,834 (2.9)Prescription of intensity of statin within the 4 weeks before the index date High76 (<0.1)23 (0.1)49 (6.6)767 (0.8)656 (1.0) Moderate14,705 (14.6)3,919 (17.9)220 (29.5)29,145 (29.5)20,717 (32.7) Low27,203 (26.9)7,494 (34.2)160 (21.5)21,724 (22.0)13,565 (21.4) None59,017 (58.4)10,471 (47.8)316 (42.4)47,225 (47.8)28,335 (44.8)Prescription of ezetimibe within the 4 weeks before the index date Yes5,135 (5.1)1,387 (6.3)179 (24.0)12,324 (12.5)9,192 (14.5) No95,866 (94.9)20,520 (93.7)566 (76.0)86,537 (87.5)54,081 (85.5)Prescription of PCSK9i within the 4 weeks before the index date Yes6 (<0.1)1 (<0.1)6 (0.8)108 (0.1)81 (0.1) No100,995 (>99.9)21,906 (>99.9)739 (99.2)98,753 (99.9)63,192 (99.9)Unless indicated otherwise, data are presented as n (%) for categorical variables, or mean±SD for continuous variables. Drug categories are defined according to the Japan Atherosclerosis Society Guidelines 2022 (JAS-GL 2022).6 ’None’ indicates patients not receiving any lipid-lowering medication listed in JAS-GL 2022. ’Statin’, ’Ezetimibe’, and ’PCSK9i/inclisiran’ denote monotherapy with the respective agent; concomitant use of agents classified as ’Other’ is permitted. ’Other’ comprises anion-exchange resins, probucol, microsomal triglyceride transfer protein inhibitors, nicotinic acid derivatives, omega-3 polyunsaturated fatty acids, and fibrates; patients in the ’Other’ category did not receive statins, ezetimibe, or PCSK9i. CCI, Charlson Comorbidity Index; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; PCSK9i, proprotein convertase subtilisin/kexin type 9 inhibitor. Table 2.Clinical Characteristics of Patients Group I (n=101,001)Group II (n=21,907)Group FH (n=745)Group III (n=98,861)Group IV (n=63,273)Sex, male50,327 (49.8)12,276 (56.0)273 (36.6)65,624 (66.4)44,010 (69.6)Age (years)71.3±13.168.2±12.959.5±8.574.5±11.274.0±11.1CCI (before the index date)2.6±2.23.2±2.21.8±1.93.1±2.33.4±2.3eGFR (mL/min/1.73 m2) n90,37621,41965290,54459,672 Mean±SD56.6±23.461.4±27.170.4±23.856.0±22.655.1±23.4CKD stage G16,101 (6.0)2,376 (10.8)106 (14.2)4,614 (4.7)3,211 (5.1) G228,991 (28.7)9,394 (42.9)353 (47.4)34,773 (35.2)21,838 (34.5) G3a31,225 (30.9)4,591 (21.0)119 (16.0)26,011 (26.3)16,517 (26.1) G3b14,840 (14.7)2,526 (11.5)52 (7.0)14,514 (14.7)10,112 (16.0) G45,424 (5.4)1,259 (5.7)12 (1.6)6,029 (6.1)4,495 (7.1) G53,795 (3.8)1,273 (5.8)10 (1.3)4,603 (4.7)3,499 (5.5)Type of lipid-lowering therapy used within the 4 weeks before the index date None49,870 (49.4)8,145 (37.2)259 (34.8)42,241 (42.7)25,362 (40.1) Statin39,695 (39.3)10,769 (49.2)278 (37.3)41,021 (41.5)26,847 (42.4) Ezetimibe2,845 (2.8)719 (3.3)27 (3.6)1,729 (1.7)1,118 (1.8) PCSK9i or inclisiran2 (<0.1)0 (0.0)3 (0.4)21 (<0.1)16 (<0.1) Statin + ezetimibe2,287 (2.3)667 (3.0)149 (20.0)10,539 (10.7)8,031 (12.7) Statin + PCSK9i1 (<0.1)0 (0.0)0 (0.0)31 (<0.1)22 (<0.1) Ezetimibe + PCSK9i2 (<0.1)1 (<0.1)1 (0.1)11 (<0.1)5 (<0.1) Statin + ezetimibe + PCSK9i1 (<0.1)0 (0.0)2 (0.3)45 (<0.1)38 (<0.1) Other6,298 (6.2)1,606 (7.3)26 (3.5)3,223 (3.3)1,834 (2.9)Prescription of intensity of statin within the 4 weeks before the index date High76 (<0.1)23 (0.1)49 (6.6)767 (0.8)656 (1.0) Moderate14,705 (14.6)3,919 (17.9)220 (29.5)29,145 (29.5)20,717 (32.7) Low27,203 (26.9)7,494 (34.2)160 (21.5)21,724 (22.0)13,565 (21.4) None59,017 (58.4)10,471 (47.8)316 (42.4)47,225 (47.8)28,335 (44.8)Prescription of ezetimibe within the 4 weeks before the index date Yes5,135 (5.1)1,387 (6.3)179 (24.0)12,324 (12.5)9,192 (14.5) No95,866 (94.9)20,520 (93.7)566 (76.0)86,537 (87.5)54,081 (85.5)Prescription of PCSK9i within the 4 weeks before the index date Yes6 (<0.1)1 (<0.1)6 (0.8)108 (0.1)81 (0.1) No100,995 (>99.9)21,906 (>99.9)739 (99.2)98,753 (99.9)63,192 (99.9)Unless indicated otherwise, data are presented as n (%) for categorical variables, or mean±SD for continuous variables. Drug categories are defined according to the Japan Atherosclerosis Society Guidelines 2022 (JAS-GL 2022).6 ’None’ indicates patients not receiving any lipid-lowering medication listed in JAS-GL 2022. ’Statin’, ’Ezetimibe’, and ’PCSK9i/inclisiran’ denote monotherapy with the respective agent; concomitant use of agents classified as ’Other’ is permitted. ’Other’ comprises anion-exchange resins, probucol, microsomal triglyceride transfer protein inhibitors, nicotinic acid derivatives, omega-3 polyunsaturated fatty acids, and fibrates; patients in the ’Other’ category did not receive statins, ezetimibe, or PCSK9i. CCI, Charlson Comorbidity Index; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; PCSK9i, proprotein convertase subtilisin/kexin type 9 inhibitor. Clinical Characteristics of Patients Unless indicated otherwise, data are presented as n (%) for categorical variables, or mean±SD for continuous variables. Drug categories are defined according to the Japan Atherosclerosis Society Guidelines 2022 (JAS-GL 2022).6 ’None’ indicates patients not receiving any lipid-lowering medication listed in JAS-GL 2022. ’Statin’, ’Ezetimibe’, and ’PCSK9i/inclisiran’ denote monotherapy with the respective agent; concomitant use of agents classified as ’Other’ is permitted. ’Other’ comprises anion-exchange resins, probucol, microsomal triglyceride transfer protein inhibitors, nicotinic acid derivatives, omega-3 polyunsaturated fatty acids, and fibrates; patients in the ’Other’ category did not receive statins, ezetimibe, or PCSK9i. CCI, Charlson Comorbidity Index; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; PCSK9i, proprotein convertase subtilisin/kexin type 9 inhibitor. The mean estimated glomerular filtration rate (eGFR) was highest in Group FH (70.4 mL/min/1.73 m2) and lowest in Group IV (55.1 mL/min/1.73 m2), with the remaining groups displaying intermediate values (approximately 56.0–61.4 mL/min/1.73 m2). When patients were stratified by CKD stage, stages G2 and G3a together accounted for the majority in every group. Prior to the index date, in the high-risk category of the primary prevention population, almost half (49.4%) of the patients in Group I had not received any LLT; this rate declined to 37.2% in Group II and was lowest in Group FH (34.8%). In the secondary prevention population, 42.7% of Group III and 40.1% of Group IV remained untreated. With respect to statin use, the proportion of patients without a statin prescription ranged from approximately 40% to 60% across all groups, with the highest rate observed in Group I (58.4%) and the lowest in Group FH (42.4%). In terms of statin strength (defined in Supplementary Table 4), high-intensity statins were virtually absent across most groups (1% or less) except in Group FH (6.6%), whereas low- and moderate-intensity statins constituted the majority of prescriptions. Notably, moderate-intensity statins were more commonly used for secondary prevention (Groups III and IV) compared with primary prevention (Groups I and II). Combination therapy with statin plus ezetimibe was uncommon in primary prevention (2.3% in Group I and 3.0% in Group II), but was frequent in secondary prevention (10.7% in Group III and 12.7% in Group IV). The patient background for each subgroup based on medical history and type of comorbidity is shown in Supplementary Table 5. Non-Achievement Rates of Target LDL-C Goals The non-achievement rates of target LDL-C goals in each group were as follows: 28.2% (95% CI 27.9–28.5) in Group I; 46.7% (95% CI 46.0–47.3) in Group II; 64.3% (95% CI 60.7–67.7) in Group FH; 30.0% (95% CI 29.7–30.3) in Group III; and 65.6% (95% CI 65.3–66.0) in Group IV (Figure 3). Group IV (target LDL-C <70 mg/dL) exhibited the highest non-achievement rate, followed by Group FH (target LDL-C <100 mg/dL) in the primary prevention population (Figure 3). Furthermore, we calculated the non-achievement rates of target LDL-C goals according to treatment category: LLT (defined here as the use of statins, ezetimibe, or proprotein convertase subtilisin/kexin type 9 inhibitors [PCSK9i]); other lipid-lowering medications (Other); and no medication (None; Supplementary Table 6). The non-achievement rates of target LDL-C levels were lower among patients receiving LLT (statins, ezetimibe, or PCSK9i) than in the other treatment categories (Other and None). Moreover, patients treated with other lipid-lowering medications (Other) showed higher non-achievement rates than patients not receiving any lipid-lowering medication (None). Figure 3.Non-achievement rates of target low-density lipoprotein cholesterol (LDL-C) goals. ACS, acute coronary syndrome; ATBI, atherothrombotic brain infarction; CAD, coronary artery disease; CKD, chronic kidney disease; DM, diabetes; FH, familial hypercholesterolemia; MCP, microangiopathy; PAD, peripheral artery disease. Non-achievement rates of target low-density lipoprotein cholesterol (LDL-C) goals. ACS, acute coronary syndrome; ATBI, atherothrombotic brain infarction; CAD, coronary artery disease; CKD, chronic kidney disease; DM, diabetes; FH, familial hypercholesterolemia; MCP, microangiopathy; PAD, peripheral artery disease. The distribution of LDL-C by risk group is presented in Figure 4. In all groups, the highest proportion of patients who had not reached the target goals were those closest to the target value. Specifically, in Group I, 8.8% of patients fell into the 120–129 mg/dL range. In Groups II, FH, and III, the proportions with LDL-C levels of 100–109 mg/dL were 12.7%, 12.3%, and 9.0%, respectively. Meanwhile, 15.1% of patients in Group IV fell into the 70–79 mg/dL range. Figure 4.Low-density lipoprotein cholesterol (LDL-C) distribution stratified by risk groups. FH, familial hypercholesterolemia. Low-density lipoprotein cholesterol (LDL-C) distribution stratified by risk groups. FH, familial hypercholesterolemia. Sensitivity Analyses When the definition of dyslipidemia was changed, the rates of non-achievement in each group were 24.4% for Group I, 42.9% for Group II, 62.8% for Group FH, 26.6% for Group III, and 63.8% for Group IV (Supplementary Figure 1). Moreover, when the definition of CAD was changed, it was 24.7% in Group I, 40.9% in Group II, 52.5% in Group FH, 28.7% in Group III, and 60.7% in Group IV (Supplementary Figure 1). In any case, similar to the results in Figure 3, Group IV showed the highest rate of non-achievement. Non-Achievement Rates of LDL-C Goals by Medical History and Comorbidities In Group I (the high-risk category in the primary prevention population), 25.8%, 27.9% and 24.8% patients in the diabetes, CKD and PAD subgroups, respectively, did not achieve the target LDL-C goal (Figure 3, Supplementary Figure 2). In Group II, 41.7% of diabetic patients with PAD, and 47.1% of diabetic patients with microangiopathy did not achieve their target. The target values for diabetic patients in primary prevention varied depending on the comorbid conditions, and compared with the diabetes subgroup in Group I, the subgroups in Group II (patients with comorbid PAD or microangiopathy) had a higher non-achievement rate. In Group III of the secondary prevention cohort, 26.0% of those with CAD and 39.2% of patients with ATBI did not achieve their targets. In Group IV, patients with CAD plus ATBI had the highest non-achievement rate (66.8%), followed by those with diabetes (66.3%), FH (60.5%), and ACS (56.6%). Non-Achievement Rates by Time Period The proportions of patients who did not achieve their LDL-C targets in each of the 5 periods are shown in Figure 5. The revised JAS-GL 2022 were implemented on July 4, 2022. Accordingly, Period 1 reflects management under the previous 2017 guidelines, whereas Periods 2–5 represent the post-revision era. Although there were minor fluctuations observed across the periods, overall non-achievement rates remained largely unchanged in all risk groups, indicating the limited impact of the guideline revision on LDL-C goal attainment during the observed timeframe. Figure 5.Non-achievement rates of target low-density lipoprotein cholesterol goals by time period: Period 1 – March 1, 2022 to July 31, 2022; Period 2 – August 1, 2022 to December 31, 2022; Period 3 – January 1, 2023 to May 31, 2023; Period 4 – June 1, 2023 to October 31, 2023; and Period 5 – November 1, 2023 to March 31, 2024. FH, familial hypercholesterolemia. Non-achievement rates of target low-density lipoprotein cholesterol goals by time period: Period 1 – March 1, 2022 to July 31, 2022; Period 2 – August 1, 2022 to December 31, 2022; Period 3 – January 1, 2023 to May 31, 2023; Period 4 – June 1, 2023 to October 31, 2023; and Period 5 – November 1, 2023 to March 31, 2024. FH, familial hypercholesterolemia. Discussion This study used a large-scale DPC database to assess the proportion of patients with dyslipidemia who did not achieve their LDL-C management goals, thereby elucidating the current status of atherosclerotic disease prevention in real-world clinical practice in Japan. The patients were categorized into risk-management target groups (under the high-risk category of primary and secondary prevention) based on the JAS-GL 2022, and we observed high proportions of non-achievement of goals across all groups. The significance of this study lies in its real-world, large-scale approach and comprehensive evaluation of treatment patterns. To our knowledge, this is the first real-world investigation based on the LDL-C management targets outlined in the JAS-GL 2022, offering a comprehensive assessment of the current landscape following guideline revision. In addition, beyond simply evaluating the use of lipid-lowering agents, we assessed treatment patterns characteristic of actual clinical practice, such as statin intensity (high, moderate, or low) and the use of combination therapy (statin plus ezetimibe). Of note, the robustness and generalizability of our primary findings are further supported by sensitivity analyses using stricter disease definitions. Specifically, we conducted 2 additional analyses: (1) restricting the dyslipidemia cohort to patients with both an ICD-10 code for dyslipidemia and at least 1 prescription for a lipid-lowering agent prior to the index date; and (2) defining CAD as cases with both an ICD-10 diagnosis code and a corresponding procedural code. Under these more stringent criteria, the non-achievement rates for LDL-C targets in each risk group remained consistent with those observed in the primary analysis, showing only minor numerical differences. This consistency underscores the robustness of our findings and suggests that potential misclassification of disease status had minimal impact on our results. In the previous study,8 the rate of LDL-C target non-achievement was evaluated based on risk stratification and management targets in accordance with the JAS-GL 2017, and it was reported that the non-achievement rates were high in the following 3 groups: high-risk individuals in primary prevention; secondary prevention; and high-risk individuals in secondary prevention. In the present study, patients were classified into 5 groups, including the newly established subcategory within the high-risk category in primary prevention defined by the JAS-GL 2022. Our analysis revealed that, even after guideline revision, the proportion of individuals not achieving target levels remained high. In all risk groups, the majority of patients who did not achieve their LDL-C target values were distributed within ranges close to the respective targets. This suggests that, after treatment, reductions in LDL-C levels to near the target may be perceived as ‘almost achieved’, which could contribute to therapeutic inertia, making further intensification of treatment less likely. However, even when LDL-C levels exceed the target by only a small margin, continued efforts to achieve the target value are important from the perspective of ASCVD event prevention. Therefore, it is necessary to further raise awareness of target achievement in clinical practice and to promote appropriate therapeutic interventions. Major contributing factors to the persistently high rate of non-achievement include the underutilization of LLT, the limited adoption of statin combination therapy with ezetimibe, and the infrequent use of maximal statin dosing in clinical practice. Another possible reason is that the maximum approved statin doses in Japan are lower than those in other countries, and the environment for medication use differs accordingly. As patients receiving LLT (statins, ezetimibe, or PCSK9i) had the lowest non-achievement rates of target LDL-C levels, these results suggest that administration of statins, ezetimibe, or PCSK9i is particularly important for achieving targets. Given that the present database cannot capture medication prescriptions from other hospitals, there is a possibility that some patients in the no medication category (None) may have received LLT at other institutions. However, the likelihood of such cases is low in the other lipid-lowering medications category (Other), which consists of lipid-lowering medications other than statins, ezetimibe, or PCSK9i. The fact that this category showed the highest non-achievement rates of target LDL-C levels further suggests the importance of statin prescription, as previously mentioned. Among patients with diabetes, target achievement rates differed between Groups I and II. Notably, Group II is a subset of Group I, comprising patients with diabetes who have additional complications – specifically, PAD or microangiopathy. These additional complications place Group II patients at an even higher risk, and accordingly, they are assigned a stricter LDL-C target of 100 mg/dL. In contrast, Group I includes patients with diabetes but without such complications, for whom the LDL-C target is set at 120 mg/dL. The lower achievement rate in Group II may be attributable not only to the more stringent LDL-C target itself, but also to insufficient physician awareness or understanding of the 100 mg/dL standard for these high-risk patients. According to the report by Haffner et al.,9 the incidence of first cardiovascular events in diabetic patients without a prior myocardial infarction is comparable with the recurrence rate in non-diabetic patients with a history of myocardial infarction, highlighting the need to reinforce education on strict lipid management for primary ASCVD prevention in diabetic patients. In Group III, patients with concomitant atherothrombotic stroke tended to have higher non-achievement rates than patients with CAD. Subgroup analyses showed that within Group III, these patients were more frequently prescribed low-intensity statins, suggesting that this pattern of lipid management may have contributed to the increased rate of target non-achievement. It is presumed that previous reports10–12 on intracerebral hemorrhage have influenced the reluctance to pursue aggressive LLT in patients with concomitant cerebrovascular disease. Many large-scale clinical trials, including the Heart Protection Study, ASCOTLLA, and JUPITER, have demonstrated that lowering LDLC levels with statins does not increase the incidence of intracerebral hemorrhage.13–15 Although the SPARCL trial reported a significant increase in intracerebral hemorrhage associated with LLT,11 subsequent stroke-specific studies – including the J-STARS trial conducted in Japanese patients and the Treat Stroke to Target (TST) trial – found no significant difference in intracerebral hemorrhage risk between the intervention and control groups.16,17 Therefore, in the context of secondary prevention after ATBI, we believe that achieving LDL-C levels below the guideline-recommended target remains warranted. Another contributing factor may be the insufficient dissemination to general practitioners that the LDL-C target of <100 mg/dL is specifically recommended for patients with ATBI, among the various stroke subtypes. Strengthening educational initiatives for general practitioners regarding these distinctions is essential to improve LDL-C target attainment rates. It is crucial that general practitioners accurately differentiate between stroke subtypes and apply appropriate lipid management strategies, particularly for patients with ischemic stroke such as those with ATBI. Group IV, which is part of the secondary prevention population, had the highest proportion of patients who did not meet their targets, and this tendency towards inadequate management in a high-risk group was consistent with the findings of the SANTORINI study.18 In Group IV, all subgroups demonstrated comparably high rates of target non-achievement. Notably, analysis of patient backgrounds revealed that the ACS subgroup had a relatively greater proportion of high-intensity statin prescriptions and use of statin–ezetimibe combination therapy. Nevertheless, the rate of target non-achievement in the ACS subgroup remained as elevated as in the other subgroups. The unmet achievement rate in Group FH was relatively high at 64.3%, despite the fact that this group had the lowest proportion (34.8%) of patients who had never received any LLT 4 weeks prior to the index date, and exhibited higher prescription rates of high-intensity statins and combination therapies compared with other groups. This finding aligns with previous reports indicating that achieving treatment goals in FH patients remains challenging.19 The exploratory analysis showed that non-achievement rates remained high and virtually unchanged before and after the guideline release across all groups. This finding suggests a possible lack of awareness or insufficient understanding of the latest guidelines among physicians. Our findings highlight the urgent need for multifaceted interventions to bridge the gap between guideline recommendations and real-world practice. Recent evidence from the United States of America demonstrates that comprehensive educational programs for primary care physicians can substantially enhance both their knowledge and confidence.20 Based on these findings, we consider it crucial to implement targeted educational initiatives for general practitioners in Japan. In particular, we recommend that academic societies intensify their outreach efforts by offering web-based seminars and developing practical clinical guidelines specifically designed for general practitioners. Such measures are likely to improve awareness of, and adherence to, the JAS-GL, thereby contributing to more effective LDL-C management in everyday clinical practice. Moreover, overcoming clinical inertia requires broad-based educational efforts to deepen understanding of each risk category’s cardiovascular significance. For patients with ACS, both domestic and international guidelines emphasize the importance of rigorous lipid management following an acute event. In Japan, specific initiatives such as ACS care pathways have been introduced to further promote optimal lipid management in this population.21 Furthermore, recent studies in Japan have demonstrated that the implementation of regional clinical alliance paths and standardized lipid management protocols significantly improve LDL-C target achievement rates in patients with acute coronary syndrome, highlighting the effectiveness of system-level interventions.22,23 Similar frameworks should be extended to other high-risk populations. Last, a multifaceted treatment approach that combines intensified statin therapy with early initiation of combination lipid-lowering agents promises to improve LDL-C target attainment across all risk groups. Continuous professional education, coupled with system-level support for treatment intensification, will be key to translating the JAS-GL 2022 into better cardiovascular outcomes. Study Limitations The present study has several limitations. First, this study used the MDV database, which was derived from acute-care hospitals, and therefore excluded data on patients with dyslipidemia managed at institutions that did not contribute to the database. Consequently, the results may not fully represent the general situation in Japan. Second, the disease and injury names in the medical-fee statement data were billing diagnoses and may not precisely correspond to the diagnoses recorded by clinicians in medical records or other documents. Third, medical procedures conducted at institutions not participating in this study were not recorded in the database used; therefore, information regarding treatments administered prior to and during the observation period may be incomplete. Last, information on smoking was omitted because it was not sufficiently recorded in the database. Conclusions This nationwide, real-world study revealed persistently high rates of non-achievement of LDL-C goals among patients with dyslipidemia across all studied risk groups, even after the implementation of the JAS-GL 2022. These findings underscore the urgent need for more effective strategies to bridge this gap and improve lipid management in high-risk cardiovascular populations. Patients who do not achieve LDL-C targets require more intensive treatment and lifelong LLT to reduce cardiovascular risk. Disclosures K.T. has received honoraria (lecture fee) from Bayer Yakuhin, Ltd, Kowa Company, Ltd, Sanofi K.K., and grant/research funding (clinical research funding) from MSD K.K. S.K. has received research funding from the Japan Society for the Promotion of Science and Pfizer, and has received consulting fees from Bristol Myers Squibb, unrelated to the submitted work. T.M., M.M., Y. Nakamura and Y. Nishimura are all employees of Otsuka Pharmaceutical Co., Ltd. S.K. is a member of Circulation Reports’ Editorial Team. IRB Information The research protocol was approved by the ethical review committee of Kitamachi Clinic, Fujikei Medical Corporation (reference no. OTH10810), and the study was registered at the University Hospital Medical Information Network under the identifier no. UMIN000058425 (https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000066250). Supplementary Files Supplementary Table 1. Supplementary Table 2. Supplementary Table 3. Supplementary Table 4. Supplementary Table 5. Supplementary Table 6. Supplementary Figure 1. Supplementary Figure 2.